

**MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL
VIRTUAL MEETING**

August 25, 2025

Minutes

Agenda Item 1

Call to Order:

Co-Chair Lorriane Diana called the meeting to order at 2:03 PM.

(Roll Call) Stakeholder Council Members Present:

Pallavi Arora, Angela Bryant, Shawn Brown, Lorraine Diana, Robert Embry, John Gambrill, Sherita Golden, Jim Gutman, Deron Johnson, Kathleen Loughran, Erica Miller, Shaun O'Brien, Amy Prentice, Kimberly Robinson, Glenn Schneider, Kelly Schultz, Danita Tolson, Sean Tunis, Joe Winn

Agenda Item 2

June 23, 2025 Meeting Minutes

Co-Chair Diana asked for a motion to approve the June 23, 2025 meeting minutes as submitted. Jim Gutman made the motion, which Dr. Tolson seconded. The PDASC unanimously approved the minutes.

Action: Minutes APPROVED

Agenda Item 3

Opportunity for Public Comment

The PDASC received 4 written comments which were shared with the PDASC and posted to the website.

The following people provided oral public comment:

1. George Huntley, Diabetes Advocacy Coalition, Agenda Item 4
2. Tiffany Westrich-Robertson- EACH/PIC Coalition, Agenda Item 4

Agenda Item 4

Cost Review Study Process Update and Next Steps- Presentation

Dr. York provided a presentation on the Cost Review Study Process Update and Next Steps, including the Board's preliminary determinations for Farxiga and Jardiance. Dr. York explained that the draft report will become available before it becomes final. Dr. York reviewed the preliminary determinations, including the circumstances the Board identified at the July 29, 2025 Board meeting under which Farxiga and Jardiance have led to affordability challenges. Dr. York reviewed the process after the Board makes a preliminary determination on affordability, which includes identifying drivers and policy options to address the drivers. Dr. York explained that

PDAB is currently in the information gathering phase. Dr. York reviewed the next steps and role of the PDASC, which includes providing input in the information gathering process within today's meeting. This presentation is posted on the Stakeholder Council page of the website.

Agenda Item 5

Board Solicited Stakeholder Council Input

Dr. York provided a presentation on Board Solicited Stakeholder Council Input to help organize the discussion among PDASC members regarding Farxiga and Jardiance. This presentation is posted on the Stakeholder Council page of the website.

The Board requested that the Stakeholder Council discuss and provide input on the following Topics in regards to Farxiga and Jardiance:

1. What driver(s) caused or contributed to each of the circumstances listed above? Explain how that driver operates in practice and how it contributed to the circumstance.
2. What information demonstrates or supports the existence of this driver?
3. Identify policies that could address this driver and how they could address the driver. For each policy, discuss:
 - a. Strengths and weaknesses of the policy;
 - b. Possible implementation of the policy through legislation, regulation, or enforcement; and
 - c. Potential impacts of the policy.

The PDASC facilitated a robust discussion around the circumstances and the drivers. PDAB staff will summarize the findings of the discussion and present that information to the Board as part of the policy review process.

Agenda Item 6

Administrative Update

- Three New PDASC Members were introduced:
 - Dr. John Gambrill, public member, appointed by Speaker Jones
 - Erica Miller, public member, appointed by the Governor
 - Robert Embry, representative of employers, appointed by the Governor
- Fee Assessment invoices will be mailed at the end of August. Those payments will be due October 1, 2025
- The September Board meeting was moved from September 15, 2025 to September 29, 2025. This meeting will be virtual.
- Dossiers were posted for Ozempic and Trulicity on 8/20/2025. Comments are being accepted through September 4, 2025. Please visit the website for more information.
- Under COMAR 14.01.05.04D(1), the Board, through staff, is convening two informational hearings to receive input, information, and opinions from the public and

stakeholders to assist the Board in developing policy to address the affordability challenges created by the use of Farxiga and Jardiance. These hearings will take place on September 3, 2025 at 1:00PM and 6:00PM

- Staff exploring the possibility of having an in person/ hybrid PDASC meeting based on feedback from a member. More information to come.

Agenda Item 7

Co-Chair's Update

- Co-Chair Diana stated that the next PDASC meeting will be on October 27, 2025.

Agenda Item 8

Adjournment

Co-Chair Diana thanked everyone for attending the meeting and asked for a motion to adjourn the meeting. Deron Johnson made the motion which was seconded by Kelly Schulz.

Adjourned at 3:46 PM.